Peer-influenced content. Sources you trust. No registration required. This is HCN.
Practical Neurology
Kisunla’s approval introduces a novel treatment option for early Alzheimer’s disease, potentially altering the landscape of AD management with its ability to significantly reduce amyloid plaque levels and slow cognitive decline.
Neurology July 17th 2024
Oncology News Central (ONC)
The FDA has approved a combination therapy of pembrolizumab, carboplatin, and paclitaxel for advanced endometrial cancer, significantly enhancing progression-free survival rates for patients with both mismatch repair deficient and proficient statuses.
Oncology, Medical July 2nd 2024
MDLinx
The FDA-approved Rejoyn app, designed for major depressive disorder, combines therapeutic exercises and emotional regulation training to complement antidepressant therapy, showing significant improvement in clinical trials.
Psychiatry May 28th 2024
Medical Professionals Reference (MPR)
Explore the FDA-cleared Modius Stress, offering groundbreaking ease in managing generalized anxiety with daily 30-minute sessions, showing significant reductions in GAD-7 scores in international clinical trials.
Psychiatry May 14th 2024
Enhertu, now FDA approved for HER2-positive solid tumors, shows a notable objective response rate across pivotal trials, providing a significant new option for patients with advanced disease stages.
Oncology, Medical May 13th 2024
Psych Congress Network
Rejoyn represents a significant advancement in the treatment of major depressive disorder, requiring prescription use and integrating brain-training exercises developed by leading mental health experts.
Psychiatry May 7th 2024